Carregant...
Spindle assembly checkpoint inhibition can resensitize p53-null stem cells to cancer chemotherapy
TP53 mutations are common in most human cancers, but few therapeutic options for TP53-mutant tumors exist. To identify potential therapeutic options for cancer patients with TP53 mutations, we profiled 127 FDA approved chemotherapy drugs against human embryonic stem cells (hESC) in which we engineer...
Guardat en:
| Publicat a: | Cancer Res |
|---|---|
| Autors principals: | , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2019
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6497569/ https://ncbi.nlm.nih.gov/pubmed/30862715 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-18-3024 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|